Background: Immunohistochemistry (IHC) based on phenotypic expression in a prospective clinical setting is expected to provide the differential status of ERG and p63 expression in benign and malignant prostatic biopsy which could be utilized as adjunct to conventional clinicopathological parameters of diagnosis, prognosis and management.
Aim: To assess the combined diagnostic utility of ERG and p63 immunohistochemistry markers expression and correlate with clinicopathological parameters in the prostatic neoplasm.
Materials &Methods: In present study, total number of 70 cases of benign prostatic hyperplasia (BPH), benign prostatic hyperplasia with prostatic intraepithelial neoplasia (BPH with PIN), prostate carcinoma was included in this study. ERG and p63 immunohistochemical staining were applied as per standard protocol on formalin fixed paraffin embedded tissue sections of prostate neoplasm and serum Prostate Specific Antigen (PSA) level was done in all the cases.
Results: Seventy cases of prostate neoplasm were included in the study. Out of 70 cases 24 (34.29%) were diagnosed as Benign Prostatic Hyperplasia, 20 (28.57%) as Prostatic Intraepithelial Neoplasia and rest 26 (37.14%) as Carcinoma Prostate. After immunohistochemical evaluation of ERG and p63, finally 21 cases of BPH, 21 cases of PIN and 28 cases of carcinoma prostate were diagnosed. ERG and p63 immunohistochemical staining as an adjunctive test along with histopathological examination increase the diagnostic accuracy almost up to 100% in our study.
Conclusion: We conclude that ERG and p63 IHC staining in prostate neoplasm also helps in early diagnosis of prostatic intraepithelial neoplasia and carcinoma prostate cases.
Impact Factor
2022: 6.012
This work is licensed under a